Strategic partnerships Navinci is actively pursuing collaborations with academic and research institutions (Uppsala University, SciLifeLab, CBCS, Pixl Bio) and industry players (Lumito) to advance spatial proteomics platforms. This presents opportunities to propose co-development, integrative workflows, or joint funding initiatives that expand Navinci’s reach and validate isPLA technology in high-profile projects.

Targeted immuno-oncology The current focus on target-specific kits for immuno-oncology such as PD1/PD-L1 suggests a sales angle around clinical and translational researchers exploring immune checkpoint interactions. Engage customers with ready-to-use kits, demonstrate spatial interaction insights, and offer training and support to accelerate adoption in cancer research pipelines.

Spatial proteomics growth Navenci’s Naveni Proximity Ligation Technology positions the company at the forefront of spatial proteomics. Position vertically to labs expanding spatial mapping capabilities and justify investments with the ability to visualize protein interactions and post-translational modifications in situ, aligning with labs pursuing precision biology and drug response mapping.

Funding and scale With a small team and <$1M revenue but $8.5M in funding, Navinci looks primed for strategic enterprise deals and channel partnerships that can scale revenue. Propose pilot programs, tiered pricing for expanding kits, and value-based bundles to help Navinci reach profitability milestones while maximizing partner-driven sales channels.

Leadership and expansion Recent leadership appointments and cross-border activities (Uppsala, Boston events, international collaborations) indicate a growth trajectory and customer engagement expansion. Target enterprise and academic buyers through executive outreach, leverage CCO-led initiatives, and offer collaboration-based licensing or co-sell opportunities to accelerate market penetration.